This database contains 244 studies, archived under the term: "Cohort Study"
Click here to filter this large number of results.
Medication adherence in patients with dementia: An Austrian cohort study
Haider, Bernhard,
Schmidt, Reinhold,
Schweiger, Christine,
Forstner, Thomas,
Labek, Anna,
Lampl, Christian
Sustained treatment with effective doses of cholinesterase inhibitors or memantine is crucial to transfer treatment effects in dementia. Numerous studies, with often small samples sizes, describe low adherence rates. The purpose of current study was to examine the medical adherence of antidementia therapy in Austria. We analyzed the data of 10 Austrian Health Insurance Funds, […]
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline
Grundman, Michael,
Pontecorvo, Michael J.,
Salloway, Stephen P.,
Doraiswamy, P. Murali,
Fleisher, Adam S.,
Sadowsky, Carl H.,
Nair, Anil K.,
Siderowf, Andrew,
Lu, Ming,
Arora, Anupa K.,
Agbulos, Abigail,
Flitter, Matthew L.,
Krautkramer, Michael J.,
Sarsour, Khaled,
Skovronsky, Daniel M.,
Mintun, Mark A.
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to […]
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease
Grossberg, G.,
Cummings, J.,
Frolich, L.,
Bellelli, G.,
Molinuevo, J. L.,
Krahnke, T.,
Strohmaier, C.
Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]
Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment
Fujiwara, Yoshinori,
Suzuki, Hiroyuki,
Yasunaga, Masashi,
Sugiyama, Mika,
Ijuin, Mutsuo,
Sakuma, Naoko,
Inagaki, Hiroki,
Iwasa, Hajime,
Ura, Chiaki,
Yatomi, Naomi,
Ishii, Kenji,
Tokumaru, Aya M,
Homma, Akira,
Nasreddine, Ziad,
Shinkai, Shoji
Aim: The Montreal Cognitive Assessment (MoCA), developed by Dr Nasreddine (Nasreddine et al. 2005), is a brief cognitive screening tool for detecting older people with mild cognitive impairment (MCI). We examined the reliability and validity of the Japanese version of the MoCA (MoCA-J) in older Japanese subjects.; Methods: Subjects were recruited from the outpatient memory […]
Can a memory club help maintain cognitive function? A pilot investigation
Fritsch, Thomas,
McClendon, McKee J.,
Wallendal, Maggie S.,
Smyth, Kathleen A.,
Geldmacher, David S.,
Hyde, Trevor F.,
Leo, Gary J.
In a pilot investigation we evaluated the impact of a structured early memory loss (EML) program intervention in a longitudinal (repeated measures) study of 55 persons with mild cognitive impairment or mild dementia. At four test sites we examined whether participation in the club—which sought to stimulate mental activity and social interaction, provide opportunities for […]
Costs of dementia in Hungary
Érsek, K.,
Kovács, T.,
Wimo, A.,
Kárpati, K.,
Brodszky, V.,
Péntek, M.,
Jönsson, L.,
Gustavsson, A.,
McDaid, D.,
Kenigsberg, P. A.,
Valtonen, H.,
Gulácsi, L.
Objective: The main aim of this paper is to give an overview on the quality of life, health care utilisation and costs of dementia in Hungary.; Method: A cross-sectional non-population based study of 88 consecutive dementia patients and their caregivers was conducted in three GP practices and one outpatient setting in 2008. Resource Utilization in […]
The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline
Donohue, Michael C.,
Sperling, Reisa A.,
Salmon, David P.,
Rentz, Dorene M.,
Raman, Rema,
Thomas, Ronald G.,
Weiner, Michael,
Aisen, Paul S
Importance: As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. Objective: To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evidence of AD pathology using the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC). The […]